文献速递冠心病外科

缺血性左心室功能不全的治疗策略:一项网络Meta分析

Treatment strategies in ischaemic left ventricular dysfunction: a network meta-analysis.
PubMed 文献 · Eur J Cardiothorac Surg · 2020-10-21

本研究通过网络Meta分析比较PCI、CABG和药物治疗在缺血性左心室收缩功能不全患者中的效果。结论主要基于观察性数据,尚需随机对照试验证实。

要点

  • 与CABG相比,PCI与更高的死亡、心源性死亡、心肌梗死和再次血运重建风险相关。
  • 与CABG相比,药物治疗与更高的死亡、心源性死亡、心肌梗死和再次血运重建风险相关。
  • CABG在死亡、心源性死亡、心肌梗死和再次血运重建方面排名最佳,药物治疗卒中发生率最低。

核心结论

  • CABG似乎是缺血性左心室收缩功能不全的最佳治疗策略,但主要基于观察性数据。
  • 需要专门比较CABG与PCI的确定性随机对照试验。

研究设计与样本

  • 频率学网络Meta分析,采用通用逆方差法。
  • 比较PCI、CABG和药物治疗的任何组合。

主要发现

  • 与CABG相比,PCI的死亡率IRR为1.32(95%CI 1.13-1.53),心源性死亡IRR为1.65(95%CI 1.18-2.33),心肌梗死IRR为2.18(95%CI 1.70-2.80),再次血运重建IRR为3.75(95%CI 2.89-4.85)。
  • 与CABG相比,药物治疗的死亡率IRR为1.52(95%CI 1.26-1.84),心源性死亡IRR为3.83(95%CI 2.12-6.91),心肌梗死IRR为3.22(95%CI 1.52-6.79),再次血运重建IRR为3.37(95%CI 1.67-6.79)。
  • 与药物治疗相比,PCI的心源性死亡IRR为0.43(95%CI 0.24-0.78)。
  • CABG在死亡、心源性死亡、心肌梗死和再次血运重建方面排名最佳;药物治疗与最低的卒中发生率相关。
  • 左心室射血分数、研究年份和药物洗脱支架的使用未影响相对治疗效果。

临床怎么用

  • 对于缺血性左心室收缩功能不全患者,CABG可作为优先考虑的血运重建策略。
  • PCI和药物治疗与CABG相比不良事件风险更高,决策时需权衡。
  • 药物治疗与最低卒中发生率相关,可作为考量因素之一。

局限性

  • 结论主要基于观察性数据,仅包含4项随机对照试验。
  • 需要确定性随机对照试验比较CABG与PCI。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The optimal revascularization strategy for patients with ischaemic left ventricular systolic dysfunction (iLVSD) remains controversial. We aimed to compare percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG) and medical therapy (MT) in a network meta-analysis. METHODS: All randomized controlled trials and observational studies comparing any combination of PCI, CABG and MT in patients with iLVSD were analysed in a frequentist network meta-analysis (generic inverse variance method). Primary outcome was mortality at longest available follow-up. Secondary outcomes were cardiac death, stroke, myocardial infarction (MI) and repeat revascularization (RR). RESULTS: Twenty-three studies were included (n = 23 633; 4 randomized controlled trials). Compared to CABG, PCI was associated with higher mortality [incidence rate ratio (IRR) 1.32, 95% confidence interval (CI) 1.13-1.53], cardiac death (IRR 1.65, 95% CI 1.18-2.33), MI (IRR 2.18, 95% CI 1.70-2.80) and RR (IRR 3.75, 95% CI 2.89-4.85). Compared to CABG, MT was associated with higher mortality (IRR 1.52, 95% CI 1.26-1.84), cardiac death (IRR 3.83, 95% CI 2.12-6.91), MI (IRR 3.22, 95% CI 1.52-6.79) and RR (IRR 3.37, 95% CI 1.67-6.79). Compared to MT, PCI was associated with lower cardiac death (IRR 0.43, 95% CI 0.24-0.78). CABG ranked as the best revascularization strategy for mortality, cardiac death, MI and RR; MT ranked as the strategy associated with the lowest incidence of stroke. Left ventricular ejection fraction, year of study, use of drug-eluting stents did not affect relative treatment effects. CONCLUSIONS: CABG appears to be the best therapy for iLVSD, although mainly based on observational data. Definitive randomized controlled trials comparing CABG and PCI in iLVSD are required. PROSPERO REGISTRATION ID: 132414.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Gaudino M, Hameed I, Khan FM, et al. Treatment strategies in ischaemic left ventricular dysfunction: a network meta-analysis. Eur J Cardiothorac Surg. 2020. PMID: 33085752. doi:10.1093/ejcts/ezaa319

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。